Immuron Ltd — Board/Management Information 2014

Dec 17, 2014

==> picture [201 x 56] intentionally omitted <==

Resignation of CEO

Melbourne, Australia – 18[th] December 2014: The Board of Australian biopharmaceutical company Immuron Limited (ASX:IMC) has today announced that it has received a letter of resignation from its Interim Chief Executive Officer (CEO) Mr. Amos Meltzer. Mr. Meltzer has agreed to be available to assist beyond his 3-month notice period, if required, to facilitate a smooth transition to a new CEO.

Immuron’s Chairman Dr. Roger Aston said “The Board is thankful for both Amos’ commitment and achievements including steering the company’s turnaround and progressing its development and commercialisation programs over the last few years. Since his commencement at Immuron in early 2010 Mr. Meltzer has filled several positions within the Company including his appointment to Interim CEO in February 2013.”

Mr Meltzer’s resignation follows the successful establishment of the platform for implementation of the clinical trial for non-alcoholic steatohepatitis (NASH). The required contractors and processes surrounding the progression of the NASH trial are now all in place, as the Company moves imminently to recruiting its first patient. The Board and the new CEO will oversee and drive the implementation and completion of the trial.

The Board will now search for a new CEO for the Company and is confident of attracting candidates with the skill and expertise appropriate to support the Company through its next stage of development. In particular, the Board believes that the time is opportune to allow the new appointee to focus on the extended marketing of its flagship product Travelan as it progresses into new overseas markets.

The future of Immuron continues to look increasingly positive as the Company moves to the next level in the development and commercialisation of its major value propositions for the benefit of shareholders and potential investors.

Contacts:

Roger Aston Non-Executive Chairman +61 (0)3 9824 5254

Investor Relations Amanda Loh, Buchan Consulting +61 (0)3 9866 4722

Websites: www.immuron.com and www.travelan.com

About Immuron

Immuron (ASX:IMC) is a Melbourne based biopharmaceutical company focused on the development of oral immunotherapy treatments using dairy-derived antibody products. Immuron has a unique technology platform producing products all with a very high safety profile. Immuron sells Travelan®, the world’s first effective over-the-counter preventative for travellers’ diarrhoea, currently available in Australia and Canada. Two Phase II trials of IMM-124E for the treatment of inflamed fatty liver diseases are about to commence. In addition, Immuron is progressing preclinical trials for IMM-529 for the treatment of Clostridium difficile infection due to the overuse of antibiotics. Immuron’s main scientific alliances are with Hadassah Medical Center (Israel) and Monash University (Australia).

Suite 1, 1233 High Street www.immuron.com Armadale, Victoria AUSTRALIA 3143 ABN: 80 063 114 045

Phone: + 61 (0)3 9824 5254 Facsimile: + 61 (0)3 9822 7735

ABN: 80 063 114 045